Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Vasospastic Angina
NCT06415227Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Vericiguat oral suspension (Formulation 4) in vasospastic angina (VSA) (2 arms), sponsored by University of Amsterdam. Primary endpoint: Area under the curve for cutaneous microvascular conductance during acetylcholine iontophoresis assessed with LASCA at 22 weeks. Started Feb 2025; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
vasospastic angina (VSA)
Beyond the preview
Go deeper on NCT06415227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415227.